Chloroquine inhibits the malignant phenotype of glioblastoma partially by suppressing TGF-beta
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Chloroquine inhibits the malignant phenotype of glioblastoma partially by suppressing TGF-beta
Authors
Keywords
Chloroquine, Glioblastoma, Transforming growth factor-beta, Cellular proliferation and invasion, Radioresistance
Journal
INVESTIGATIONAL NEW DRUGS
Volume 33, Issue 5, Pages 1020-1031
Publisher
Springer Nature
Online
2015-08-14
DOI
10.1007/s10637-015-0275-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pharmacokinetic Interactions between Primaquine and Chloroquine
- (2014) Sasithon Pukrittayakamee et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs
- (2014) Pengfei Jiang et al. Journal of Translational Medicine
- Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab
- (2014) R. Rahman et al. NEURO-ONCOLOGY
- Transforming growth factor-beta and its implication in the malignancy of gliomas
- (2014) Laurent-Olivier Roy et al. Targeted Oncology
- Plasmodium vivax Chloroquine Resistance and Anemia in the Western Brazilian Amazon
- (2013) Marly M. Marques et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Hypoxia-Induced Autophagy Promotes Tumor Cell Survival and Adaptation to Antiangiogenic Treatment in Glioblastoma
- (2012) Y.-L. Hu et al. CANCER RESEARCH
- Resistance of Glioblastoma-Initiating Cells to Radiation Mediated by the Tumor Microenvironment Can Be Abolished by Inhibiting Transforming Growth Factor-β
- (2012) Matthew E. Hardee et al. CANCER RESEARCH
- Infiltration of glioma cells in brain parenchyma stimulated by radiation in the F98/Fischer rat model
- (2012) Guillaume Desmarais et al. INTERNATIONAL JOURNAL OF RADIATION BIOLOGY
- Current clinical development of PI3K pathway inhibitors in glioblastoma
- (2012) P. Y. Wen et al. NEURO-ONCOLOGY
- CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2005-2009
- (2012) T. A. Dolecek et al. NEURO-ONCOLOGY
- Chloroquine or Chloroquine-PI3K/Akt Pathway Inhibitor Combinations Strongly Promote γ-Irradiation-Induced Cell Death in Primary Stem-Like Glioma Cells
- (2012) Elke Firat et al. PLoS One
- Improving the prediction of the brain disposition for orally administered drugs using BDDCS
- (2011) Fabio Broccatelli et al. ADVANCED DRUG DELIVERY REVIEWS
- Chemoresistance of glioblastoma cancer stem cells - much more complex than expected
- (2011) Dagmar Beier et al. Molecular Cancer
- Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells
- (2011) E. L. Kim et al. NEURO-ONCOLOGY
- TGF-β Receptor Inhibitors Target the CD44high/Id1high Glioma-Initiating Cell Population in Human Glioblastoma
- (2010) Judit Anido et al. CANCER CELL
- TGF-β Increases Glioma-Initiating Cell Self-Renewal through the Induction of LIF in Human Glioblastoma
- (2009) Silvia Peñuelas et al. CANCER CELL
- PTEN/PI3K/Akt Pathway Regulates the Side Population Phenotype and ABCG2 Activity in Glioma Tumor Stem-like Cells
- (2009) Anne-Marie Bleau et al. Cell Stem Cell
- Systemic Inhibition of Transforming Growth Factor- in Glioma-Bearing Mice Improves the Therapeutic Efficacy of Glioma-Associated Antigen Peptide Vaccines
- (2009) R. Ueda et al. CLINICAL CANCER RESEARCH
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
- (2009) Roger Stupp et al. LANCET ONCOLOGY
- Malignant Gliomas in Adults
- (2008) Patrick Y. Wen et al. NEW ENGLAND JOURNAL OF MEDICINE
- An Integrated Genomic Analysis of Human Glioblastoma Multiforme
- (2008) D. W. Parsons et al. SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started